Oppenheimer raised the price target for the PMV Pharmaceuticals Inc. (NASDAQ:PMVP) stock from “a Perform” to “an Outperform”. The rating was released on March 02, 2022, according to finviz. We previously noted in another research note published on September 22, 2021 by Goldman that upgraded the stock from a Neutral to a Buy with a price target of $43 for PMVP stock. The stock was initiated by Guggenheim, who disclosed in a research note on August 02, 2021, to Buy and set the price objective to $56. In their research brief published July 29, 2021, H.C. Wainwright analysts initiated the PMV Pharmaceuticals Inc. stock to Buy with a price target of $63.
The latest trade, Performances and Moving Averages give us the following Picture
The share price of PMV Pharmaceuticals Inc. (NASDAQ:PMVP) dipped -1.77% to close Wednesday’s market session at $5.55, lower as compared to yesterday’s close. The stock price fluctuated between $5.38 and $5.71 throughout the trading session with the volume trading being 1195873 shares, which represented a significant variation when compared to the three months average volume of 580.35K shares. The firm’s stock price fluctuated -5.29% within the last five trades and -27.55% within the last 30 trades, which was a significant change from the beginning of this year. Despite the fact that the share price decreased -58.43% in the last 6 months and -43.02% was subtracted to its value over the previous 3 months. PMVP stock is trading at a margin of -16.10%, -26.56% and -50.74% apart from the 20-Day, 50-Day and 200-Day Simple Moving Average prices.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Sponsored
As of the close of trading, PMVP deals in the Healthcare domain. The stock is trading -77.13 percent below its 52-week high and 9.04 percent above its 52-week low. For example, looking both at the price and the high and low measurements of 52 weeks will give you a clearer picture of the direction the price is heading. The firm’s Weighted Alpha is -73.2. A positive weighted alpha indicates the firm has done well over the course of the year, whereas one below 0 indicates that the firm has done poorly.
What Does PMV Pharmaceuticals Inc.’s Profitability and Valuation Ratios Tell Us About the Stock?
The stock’s market cap achieved a total value of $258.74 million as of the last trading session. Market capitalization is the total value of all outstanding shares of a corporation and it is used to measure a company’s market value. The firm managed a Price-to-Book ratio of 1.03, which equates the market value of a stock with its book value.
Is Insider Trading a Real Thing?
ORBIMED ADVISORS LLC, the 10% Owner at PMV Pharmaceuticals Inc. (PMVP) has sold 26,253 shares of firm on May 26 at a price of $15.93 against the total amount of $0.42 million. In another inside trade, ORBIMED ADVISORS LLC, 10% Owner of PMV Pharmaceuticals Inc. (NASDAQ:PMVP) sold 34,500 shares of the firm on Mar 31 for a total worth of $0.73 million at a price of $21.17. An inside trade which took place on Mar 30, 10% Owner of PMV Pharmaceuticals Inc. ORBIMED ADVISORS LLC sold 75,000 shares of firm against total price of $1.68 million at the cost of $22.39 per share.